HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ StudyIvonne Haffner, Florian Lordick, Axel Walch et al.|Journal of Clinical Oncology|2021Cited by 124
Abstract 2615: Heterogeneity of HER2 expression in gastric cancer (GC) leads to high deviation rates between local and central testing and hampers efficacy of anti-HER2 therapy: Survival results from the VARIANZ studyFlorian Lordick, Christian Wittekind, Ivonne Haffner et al.|Cancer Research|2018Cited by 5
Central validation of HER2 status to determine heterogeneity of marker expression in HER2-positive gastric cancer (GC).Ivonne Haffner, Florian Lordick, Birgit Luber et al.|Journal of Clinical Oncology|2017Cited by 0
Patient-reported quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Interim results of the TALLISUR study.Meinolf Karthaus, Stefan Fuxius, Jorge Riera Knorrenschild et al.|Journal of Clinical Oncology|2021Cited by 0